BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Novartis Combo could be New Standard of Care for Pediatric Glioma Patients

  Results of a Phase II/III study showed that patients who were given Tafinlar plus Mekinist saw an overall response rate of 47% vs. 11% for those who received standard chemotherapy only.

  June 7, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Lilly’s Mounjaro Bests Novo’s Diabetes Drugs in Comparison Study

  The Phase I mechanism of action study, showing that Lilly’s injectable Mounjaro (tirzepatide) induces greater weight loss than placebo and Novo Nordisk’s semaglutide in adults with type 2 diabetes.

  June 7, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Seres Touts Strong Phase III Results Against Recurrent C. Difficile Infection

  Seres Therapeutics, Inc. announced that the company’s Phase III Ecospor IV study demonstrated a strong safety profile in addition to statistically significant positive results against C. difficile infection.

  June 7, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Code Bio Launches with $75M to Disrupt Gene Therapy Space

  Code Bio, a biotechnology company leading the way in targeted non-viral delivery of generic medicines, closed a $75 million Series A financing round on Tuesday.

  June 7, 2022

   · 

  2 min read

   · 

  Paolo Besabella
• 

  Policy

  Novartis Latest Target in Cyberattack Extortion Plot

  Novartis has fallen victim to a cyberattack. The Swiss pharma giant’s data was hijacked by a well-known online extortion ring dubbed Industrial Spy.

  June 7, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Amarin, Vincerx Cut Jobs in Effort to Extend Cash Flow

  Amarin and Vincerx Pharma intend to restructure their financial strategies and lessen operational costs by trimming their employee rosters.

  June 7, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano
• 

  Policy

  bluebird bio Blazes Trail for Lentiviral Vectors at Upcoming FDA Meeting

  For the first time in half a decade, the FDA will convene to address two therapies developed by bluebird bio that could have ripple effects across the industry regarding lentiviral vectors.

  June 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Research Shows Stem Cells Might Become a Game Changer for Multiple Sclerosis

  The Tisch MS Research Center of New York has been researching the concept of using cell therapy as a therapeutic strategy to promote repair and regeneration in certain patients with MS.

  June 7, 2022

   · 

  7 min read

   · 

  Kaley Lefevre
• 

  Drug Development

  CEL-SCI, Jazz, CARsgen, Ascentage and Portage Showcase New Data at ASCO

  CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.

  June 7, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Sernova Cell Pouch Keeps T1 Diabetes Patient Insulin Free for 2 Years

  Sernova shared positive Phase I/II data from an ongoing clinical study of its implantable Cell Pouch device that showed evidence of in vivo active insulin production.

  June 7, 2022

   · 

  4 min read

   · 

  Alex Keown